

Equity Research Desk

Indices	Value	Pts	Chg (%)
SENSEX	49580.7	848.2	1.74
NIFTY	14923.2	245.4	1.67
SGX NIFTY*	15121.0	165.6	1.11
DOW Jones	34327.8	(54.3)	-0.16
S&P	4163.3	(10.6)	-0.25
Nasdaq	13379.1	(50.9)	-0.38
FTSE	7032.9	(10.8)	-0.15
CAC	6367.4	(17.8)	-0.28
DAX	15396.6	(20.0)	-0.13
Shanghai Composite*	5168.0	(17.0)	-0.33
Nikkei*	28399.6	574.8	2.07
Hang Seng*	28530.7	336.7	1.19

*As at 8.00 am

Most Active Call & Put			
Symbol	Strike Price	OI (000)	Chg (%)
NIFTY	15000CE	46265	1.2
NIFTY	14700PE	52948	53.1

Commodity	Price	Pts	Chg (%)
NYMEX Crude (USD)	66.4	0.2	0.3
Brent Crude (USD)	69.7	0.2	0.3
Gold (USD)	1870.9	3.3	0.2
Silver (USD)	28.66	0.39	1.37
Copper (USD)	474.95	3.8	0.81
Cotton (USD)	83.08	0.76	0.92

Currency	Value	Pts	Chg (%)
USD/Rupee	73.30	-0.02	-0.02
Euro/Rupee	89.19	0.03	0.03
Pound/Rupee	103.85	0.19	0.19
USD/Euro	1.22	0.12	0.10
Dollar Index	90.11	-0.06	-0.06

Indicators	Value	Pts	Chg (%)
CBOE VIX	19.7	0.9	4.8
India VIX	19.6	-0.7	-3.3

Indicators	Value	Bps chg
India 10-Yr Yield	5.97	-1.4
US 10-Yr Yield	1.65	4.0

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	5640	76045	3306583
Advance (Nos)	23	39	NA
Declines (Nos)	7	11	NA
Unchanged	0	0	NA

Market Summary

Tracking favourable cues from Asian peers and a further decline in fresh Covid cases in the country, Indian benchmark indices eyed a gap-up start to the session on Tuesday with SGX Nifty ruling 166 points higher at 15,121. Furthermore, stock-specific news flows and quarterly earnings are also likely to sway market mood.

India for the second consecutive day reported cases below the 3 lakh mark. The fresh case count in the last 24 hours stood at 2.63 lakh versus 2.81 lakh on Monday.

Meanwhile, on the global market front, Wall Street ended lower overnight, weighed down by tech shares as signs of growing inflation worried investors about the potential for tighter monetary policy. The Dow Jones Industrial Average fell 0.16%, the S&P 500 lost 0.25% and the Nasdaq Composite dropped 0.38%. Despite a weak close for US markets, Asian stocks and US futures rose as investors weighed the pace of growth as nations vaccinate and economies reopen against a pick-up in virus cases in the region. Nasdaq 100 futures gained 0.4%, Topix index rose 1.5%, Australia's S&P/ASX 200 Index added 0.6% and Kospi index climbed 1.1%.

Tata Motors, Aarti Industries, Chalet Hotels, Canara Bank and Torrent Pharma are among 35 companies slated to post their March quarter results today.

Analysts expect Tata Motors to report a strong standalone performance, offset by modest performance in JLR. On a consolidated basis, they are pencilling in a 41 per cent YoY increase in the company's top-line and a profit of up to Rs 2,813 crore.

Bharti Airtel reported a consolidated net profit of Rs 759 crore in the fourth quarter of 2020-21 as against a loss of Rs 5,237 crore in the corresponding period of 2019-20. Airtel's average revenue per user (ARPU) stood at Rs 145, down from Rs 166 sequentially and Rs 154 in the year-ago period.

Macro News

WPI inflation hits double digits in April at 10.49%; crude prices harden

The wholesale price-based inflation shot up to an all-time high of 10.49 per cent in April, on rising prices of crude oil and manufactured items. Also, a low base of April last year contributed to the spike in inflation in April 2021. The WPI inflation was 7.39 per cent in March 2021, and (-) 1.57 per cent in April 2020. This is the fourth straight month of uptick seen in the wholesale price index (WPI)-based inflation.

Covid vaccines: Medical refrigerators makers gearing up to meet mkt needs

Leading medical refrigerator makers such as Godrej Appliances, Voltas and Blue Star are gearing up to cater to needs of Covid vaccine manufacturers by enhancing their cooling technologies in view of the requirement to store vaccines at ultra-low temperatures. Such refrigerator companies are also looking to ramp up their production capacity in anticipation of growing demand of new-age medical refrigerators that can preserve vaccines at a temperature of as low as minus 80 degrees celsius. Medical refrigerator manufacturers, which have witnessed a substantial jump in their business after India started the vaccination programme with Covishield and Covaxin, are now open to form tie-ups with the pharma companies that are importing coronavirus vaccines.

Gems, jewellery exports surge to Rs 25,226 cr in April: GJEPC

The demand for gem and jewellery is back in major export markets, as the overall shipments of gems and jewellery surged to Rs 25,226.11 crore year-on-year in April 2021, according to Gem and Jewellery Export Promotion Council (GJEPC). The overall gems and jewellery exports stood at Rs 273.41 crore during April 2020, when India as well as the major export markets were going through lockdowns to curb the spread of COVID-19, GJEPC data showed.

Equity Research Desk

Key News

Colgate-Palmolive India Q4 net profit jumps 54% to Rs 314.6 crore

Consumer goods major Colgate-Palmolive India on Monday reported a 54.1 per cent increase in its net profit to Rs 314.6 crore in Q4 versus a year ago, helped by a low base and all-round growth across categories. Its net sales were up 20.2 per cent YoY to Rs 1,275.01 crore in Q4, versus Rs 1,062.35 crore in the year-ago period. Ram Raghavan, managing director at Colgate-Palmolive (India), said the company continued to witness strong momentum across segments. "Our focused approach to executing our strategic initiatives has been instrumental in our continued abilities to sustain our growth momentum versus year ago as well as on a sequential basis," he said.

Bharti Airtel reports consolidated net profit of Rs 759 crore in Q4

Bharti Airtel on Monday reported a consolidated net profit of Rs 759 crore in the fourth quarter of 2020-21, after provisioning for the adjusted gross revenue (AGR) payment due to the central government. The telecom operator had posted a loss of Rs 5,237 crore in the corresponding period of 2019-20. In the third quarter of FY21, the company had posted a consolidated net profit of Rs 854 crore, helped by an one-time gain from the merger of Indus Towers.

Orient Cement Q4 net profit rises over two-folds to Rs 99.87 crore

C K Birla group firm Orient Cement Ltd on Monday reported an over two-fold jump in net profit at Rs 99.87 crore in the fourth quarter ended March 2021. It had posted a net profit of Rs 44.06 crore in the January-March quarter a year ago, Orient Cement said in a BSE filing. Its revenue from operation rose 27.06 per cent to Rs 831.61 crore during the quarter under review as against Rs 654.52 crore in the corresponding period a year earlier. Total expenses were at Rs 680.83 crore in Q4/FY2020-21, up 14.96 per cent as against Rs 654.52 crore.

Gland Pharma's Q4 consolidated net profit up 34% at Rs 260.4 crore

Drug firm Gland Pharma on Monday reported a 34 per cent rise in its consolidated net profit to Rs 260.4 crore for the fourth quarter ended March 2021, on account of robust sales. The company had posted a net profit of Rs 194.8 crore for the corresponding period of the previous fiscal, Gland Pharma said in a BSE filing. Consolidated revenue from operations of the company stood at Rs 887.7 crore for the quarter under consideration. It was Rs 635.2 crore in the year-ago period, it added.

Federal Bank posts best ever quarterly net profit, up 59% at Rs 477 cr

Kochi-headquartered private sector lender Federal Bank has reported a 59 per cent year-on-year (YoY) growth in net profit in the March quarter of FY21 due to lower provisions and a steady net interest income (NII). The banks' net profit for the period was Rs 477.81 crore, its highest ever in a quarter, compared to Rs 301.23 crore a year ago.

Tata Motors Jamshedpur plant to undergo block closure from May 18-22

Homegrown automobile giant Tata Motors will undertake a block closure at its Jamshedpur facility from May 18 to May 22, as per an internal communication sent to its employees on Monday. The employees have been asked to report for duty on May 24. The announcement comes ahead of the company's board meeting scheduled on May 18 to consider and approve the audited financial results for the quarter and financial year ended March 31. A Tata Motors spokesperson confirmed the block closure saying that it is a routine closure for "maintenance".

Institutional Activity	Cash	
	17-May-21	14-May-21
FIIs (INR Crs)		
Buy	5797.54	5856.40
Sell	8053.38	8464.25
Net	(2255.84)	(2607.85)
DII (INR Crs)		
Buy	7096.88	5444.16
Sell	5148.40	4830.90
Net	1948.48	613.26

FII Derivative Statistics

Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)
INDEX FUTURES	4808.18	4182.97	113668
INDEX OPTIONS	248258.28	243614.34	1049684
STOCK FUTURES	15428.04	16330.09	1400380
STOCK OPTIONS	21068.15	21409.21	232293
Total	289562.65	285536.61	

Gainers & Losers	Price	Chg (%)
Gainers (INR)		
INDUSINDBK	958.00	7.54
SBIN	384.45	6.66
ICICIBANK	623.90	4.45
HDFCBANK	1439.00	3.76
AXISBANK	708.65	3.45
Losers (INR)		
CIPLA	883.45	-2.28
BHARTIARTL	547.80	-2.25
LT	1388.40	-1.91
SBILIFE	964.70	-1.40
NESTLEIND	17060.00	-0.95

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	22558.92	358.38	1.61
S&P BSE Mid-Cap	20842.20	334.41	1.63
S&P BSE Auto	22449.62	418.45	1.90
S&P BSE BANKEX	38058.27	1458.36	3.98
S&P BSE Capital Goods	21468.24	133.94	0.63
S&P BSE FMCG	13015.45	25.03	0.19
S&P BSE Healthcare	24089.32	-1.30	-0.01
S&P BSE IT	26341.69	210.13	0.80
S&P BSE Metals	19140.10	363.04	1.93
S&P Oil & Gas	15681.30	97.97	0.63

Equity Research Desk

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Arete Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: Arete Securities Limited (hereinafter refer as Arete Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. Arete Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MSEI for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasec.in

Arete Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. Vide SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by Arete Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through Arete Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by Arete Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither Arete Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Arete Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

Arete Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject Arete Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of Arete Securities.

List of Associates as per SEBI (Research Analyst) Regulations, 2014

Statements on ownership and material conflicts of interest, compensation - Arete and Associates

Disclosure of interest statement	Yes/No
Arete Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
Arete Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month. Immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by Arete Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
<ul style="list-style-type: none"> Managing/co-managing public offering of securities Investment banking/merchant banking/brokerage services products or services other than those above in connection with research report 	No
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

ARETE Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

ARETE GLOBAL PRIVATE LIMITED

Mutual Fund Advisor
AMFI Reg. No. 90796

ARETE SECURITIES LTD	SEBI REG. NOS.
NSE Cash	INZ000241036
NSE Future & Option	INZ000241036
NSE Currency Derivatives	INZ000241036
BSE Cash	INZ000241036
MSEI Cash	INZ000241036
Mutual Fund	ARN 77388
NSDL DP	IN-DP-NSDL-316-2009
SEBI Research Analyst	INH100002615
Merchant Banker	INM000012740